Fibrogenesis in kidney transplantation: Potential targets for prevention and therapy

Transplantation

Volumn 88, Issue 10, 2009, Pages 1149-1156

  Djamali, Arjang ^a   Samaniego, Millie ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

EMT; Fibrosis; TGF

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ALEMTUZUMAB; ALPHA TOCOPHEROL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; ANTIOXIDANT; APOCYNIN; ARGININE; BASILIXIMAB; BELATACEPT; CHEMOKINE; CHEMOKINE RECEPTOR ANTAGONIST; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHENYLIODONIUM SALT; LOSARTAN; MET RANTES ANTAGONIST; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIRFENIDONE; PROTEIN INHIBITOR; RAPAMYCIN; SMAD3 INHIBITOR; SMALL INTERFERING RNA; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA 1 ANTAGONIST; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANEMIA; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL INFILTRATION; CELLULAR IMMUNITY; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MECHANISM; FIBROGENESIS; FIBROSING ALVEOLITIS; FOCAL GLOMERULOSCLEROSIS; GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS; HUMAN; HUMORAL IMMUNITY; HYPERTENSION; ISCHEMIA; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT FIBROSIS; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; KIDNEY INJURY; KIDNEY PARENCHYMA; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MONOTHERAPY; MULTIPLE SCLEROSIS; NEOPLASM; NEPHROTIC SYNDROME; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEINURIA; PSORIASIS; REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; UNSPECIFIED SIDE EFFECT; URETER OBSTRUCTION; WOUND HEALING IMPAIRMENT;

CHEMOKINES; FIBROSIS; GRAFT REJECTION; HUMANS; IMMUNITY, HUMORAL; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PHENYLUREA COMPOUNDS; PIPERIDINES; RECEPTORS, CHEMOKINE; SIROLIMUS; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA;

EID: 73849095809     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181bcccea     Document Type: Review

References (69)

1. Cosio FG, Grande JP, Wadei H, et al. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5: 2464.
2. Bottinger EP. TG. F-beta in renal injury and disease. Semin Nephrol 2007; 27: 309.
3. Bedi S, Vidyasagar A, DjamaliA. Epithelial-to-mesenchymal transition and chronic allograft tubulointerstitial fibrosis. Transplant Rev (Orlando) 2008; 22: 1.
4. Hertig A, Anglicheau D, Verine J, et al. Early epithelial phenotypic changes predict graft fibrosis. J Am Soc Nephrol 2008; 19: 1584.
5. Kalluri R. EMT: When epithelial cells decide to become mesenchymal-like cells. J Clin Invest 2009; 119: 1417.
6. Grande MT, Lopez-Novoa JM. Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat Rev Nephrol 2009; 5: 319.
7. Bedke J, Kiss E, Schaefer L, et al. Beneficial effects of CCR1 blockade on the progression of chronic renal allograft damage. Am J Transplant 2007; 7: 527.
8. Anders HJ, Belemezova E, Eis V, et al. Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice. J Am Soc Nephrol 2004; 15: 1504.
9. Vielhauer V, Berning E, Eis V, et al. CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and ne-phrotic syndrome. Kidney Int 2004; 66: 2264.
10. Anders HJ, Vielhauer V, Frink M, et al. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Invest 2002; 109: 251.
11. Song E, Zou H, Yao Y, et al. Early application of Met-RANTES ameliorates chronic allograft nephropathy. Kidney Int 2002; 61: 676.
12. Ruster C, Wolf G. The role of chemokines and chemokine receptors in diabetic nephropathy. Front Biosci 2008; 13: 944.
13. Djamali A. OS as a common pathway to chronic tubulointerstitial injury in kidney allografts. Am J Physiol Renal Physiol 2007; 293: F445.
14. Rhyu DY, Yang Y, Ha H, et al. Role of reactive oxygen species in TGF-beta1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells. J Am Soc Nephrol 2005; 16: 667.
15. Djamali A, Vidyasagar A, Adulla M, et al. Nox-2 is a modulator of fibrogenesis in kidney allografts. Am J Transplant 2009; 9: 74.
16. Albrecht EW, van Goor H, Smit-van Oosten A, et al. Long-term dietary L-arginine supplementation attenuates proteinuria and focal glomerulo-sclerosis in experimental chronic renal transplant failure. Nitric Oxide 2003; 8: 53.
17. Gottmann U, Oltersdorf J, Schaub M, et al. Oxidative stress in chronic renal allograft nephropathy in rats: Effects of long-term treatment with carvedilol, BM 910228, or alpha-tocopherol. J Cardiovasc Pharmacol 2003; 42: 442.
18. Land W, Schneeberger H, Schleibner S, et al. The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation 1994; 57: 211.
19. Pollak R, Andrisevic JH, Maddux MS, et al. A randomized double-blind trial of the use of human recombinant superoxide dismutase in renal transplantation. Transplantation 1993; 55: 57.
20. Mulay AV, Hussain N, Fergusson D, et al. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: A systematic review of randomized trials. Am J Transplant 2005; 5: 1748.
21. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to cal-cineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
22. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative cam-path 1H, and low-dose cyclosporine monotherapy in renal allograft recipients. Lancet 1998; 351: 1701.
23. Knechtle SJ, Pirsch JD, Fechner H, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003; 3: 722.
24. Ciancio G, Burke GW III. Alemtuzumab (Campath-1H) in kidney transplantation. Am J Transplant 2008; 8: 15.
25. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770.
26. Larsen FV, Grinyo JM, Charpentier B, et al. Renal benefit of belatacept vs cyclosporine in kidney transplant patients is not impacted by acute rejection (BENEFIT Study). Am J Transplant 2009; abstr 100.
27. Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in ox-idative stress and atherogenesis, part I: Oxidative stress and atherogen-esis. Circulation 2002; 105: 393.
28. Bhaskaran M, Reddy K, Radhakrishanan N, et al. Angiotensin II induces apoptosis in renal proximal tubular cells. Am J Physiol Renal Physiol 2003; 284: F955.
29. Chabrashvili T, Kitiyakara C, Blau J, et al. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol 2003; 285: R117.
30. Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: A key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 2006; 24: 11.
31. Amuchastegui SC, Azzollini N, Mister M, et al. Chronic allograft ne-phropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. J Am Soc Nephrol 1998; 9: 1948.
32. Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17: 889.
33. Opelz G, Zeier M, Laux G, et al. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: A Collaborative Transplant Study Report. J Am Soc Nephrol 2006; 17: 3257.
34. Hiremath S, Fergusson D, Doucette S, et al. Renin angiotensin system blockade in kidney transplantation: A systematic review of the evidence. Am J Transplant 2007; 7: 2350.
35. ZavadilJ, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005; 24: 5764.
36. Tyler JR, Robertson H, Booth TA, et al. Chronic allograft nephropathy: Intraepithelial signals generated by transforming growth factor-beta and bone morphogenetic protein-7. Am J Transplant 2006; 6: 1367.
37. Mannon RB, Kopp JB, Ruiz P, et al. Chronic rejection of mouse kidney allografts. Kidney Int 1999; 55: 1935.
38. Khanna AK, Cairns VR, Becker CG, et al. Transforming growth factor (TGF)-beta mimics and anti-TGF-beta antibody abrogates the in vivo effects of cyclosporine: Demonstration of a direct role of TGF-beta in immunosuppression and nephrotoxicity of cyclosporine. Transplantation 1999; 67: 882.
39. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-beta1 gene resultsin multifocal inflammatory disease. Nature 1992; 359: 693.
40. Eikmans M, Sijpkens YW, Baelde HJ, et al. High transforming growth factor-beta and extracellular matrix mRNA response in renal allografts during early acute rejection is associated with absence of chronic rejection. Transplantation 2002; 73: 573.
41. Shimizu T, Fukagawa M, Kuroda T, et al. Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int Suppl 1997; 63: S239.
42. Shimizu T, Kuroda T, Hata S, et al. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int 1998; 54: 99.
43. Shihab FS, Bennett WM, Yi H, et al. Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transplant 2002; 2: 111.
44. Liu H, Drew P, Gaugler AC, et al. Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway. Am J Transplant 2005; 5: 1256.
45. Cho ME, Smith DC, Branton MH, et al. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007; 2: 906.
46. Wakino S, Kanda T, Hayashi K. Rho/Rho kinase asapotential target for the treatment of renal disease. Drug News Perspect 2005; 18: 639.
47. Sato M, Muragaki Y, Saika S, et al. Targeted disruption of TGF-beta1/ Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003; 112: 1486.
48. Nagatoya K, Moriyama T, Kawada N, et al. Y-27632 prevents tubulo-interstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int 2002; 61: 1684.
49. Ishimaru K, Ueno H, Kagitani S, et al. Fasudil attenuates myocardial fibrosis in association with inhibition of monocyte/macrophage infiltration in the heart of DOCA/salt hypertensive rats. J Cardiovasc Pharmacol 2007; 50: 187.
50. Kikuchi Y, Yamada M, Imakiire T, et al. A rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J Endocrinol 2007; 192: 595.
51. Satoh S, Yamaguchi T, Hitomi A, et al. Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction. Eur J Pharmacol 2002; 455: 169.
52. Grotendorst GR. Connective tissue growth factor: A mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev 1997; 8: 171.
53. Nguyen TQ, Roestenberg P, van Nieuwenhoven FA, et al. CTGF inhibits BMP-7 signaling in diabetic nephropathy. J Am Soc Nephrol 2008; 19: 2098.
54. Cheng O, Thuillier R, Sampson E, et al. Connective tissue growth factor is a biomarker and mediator of kidney allograft fibrosis. Am J Transplant 2006; 6: 2292.
55. Luo GH, Lu YP, Song J, et al. Inhibition of connective tissue growth factor by small interfering RNA prevents renal fibrosis in rats undergoing chronic allograft nephropathy. Transplant Proc 2008; 40: 2365.
56. Ivkovic S, Yoon BS, Popoff SN, et al. Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development 2003; 130: 2779.
57. Nakagawa T. Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: An explanation for the paradoxical effects of VEGF in renal disease. Am J Physiol Renal Physiol 2007; 292: F1665.
58. Longo R, Gasparini G. Anti-VEGF therapy: The search for clinical bi-omarkers. Expert Rev Mol Diagn 2008; 8: 301.
59. Ozdemir BH, Ozdemir FN, Haberal N, et al. Vascular endothelial growth factor expression and cyclosporine toxicity in renal allograft rejection. Am J Transplant 2005; 5(4 pt 1): 766.
60. Mizuno S, Matsumoto K, Nakamura T. HGF as a renotrophic and anti-fibrotic regulator in chronic renal disease. Front Biosci 2008; 13: 7072.
61. Liu Y. Hepatocyte growth factor in kidney fibrosis: Therapeutic potential and mechanisms ofaction. AmJ Physiol Renal Physiol 2004; 287: F7.
62. Azuma H, Takahara S, Matsumoto K, et al. Hepatocyte growth factor prevents the development of chronic allograft nephropathy in rats. J Am Soc Nephrol 2001; 12: 1280.
63. Herrero-Fresneda I, Torras J, Franquesa M, et al. HGF gene therapy attenuates renal allograft scarring bypreventing the profibrotic inflammatory-induced mechanisms. Kidney Int 2006; 70: 265.
64. Powell RJ, Simons M, Mendelsohn FO, et al. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008; 118: 58.
65. Benvenuti S, Comoglio PM. The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 2007; 213: 316.
66. Mitu G, Hirschberg R. Bone morphogenetic protein-7 (BMP7) in chronic kidney disease. Front Biosci 2008; 13: 4726.
67. Zeisberg M, Hanai J, Sugimoto H, et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003; 9: 964.
68. Zeisberg M, Kalluri R. Reversal of experimental renal fibrosis by BMP7 provides insights into novel therapeutic strategies for chronic kidney disease. Pediatr Nephrol 2008; 23: 1395.
69. Hsu WK, Wang JC. The use of bone morphogenetic protein in spine fusion. Spine J 2008; 8: 419.